Latest Payments News

MinRex Resources is advancing a transformative merger with Canadian explorer Electrum Discovery Corp., poised to create a well-capitalised gold and copper exploration entity with significant assets in Serbia and Australia.

Findi Limited has responded in detail to ASX queries over its valuation approach for its Indian subsidiary TSI, clarifying peer selection, valuation multiples, and compliance ahead of TSI’s planned IPO on the Bombay Stock Exchange.

Midas Minerals has reported promising high-grade copper and silver mineralisation at its newly acquired Otavi Copper Project in Namibia, with ongoing drilling and new targets shaping a compelling exploration narrative.

SIV Capital Limited posted a negative operating cash flow of $115,000 for the December quarter, maintaining a strong cash balance of nearly $8 million despite its securities suspension by ASX.

Region Group (RGN) has outlined the tax breakdown of its 6.9 cents per security distribution for the half year ended December 2025, clarifying implications for non-resident investors and withholding tax obligations.

Emmerson Resources has reported a significant increase in its White Devil gold resource at Tennant Creek and kicked off feasibility studies alongside a $6.9 million exploration budget for early 2026.

BKI Investment Company reported a solid half-year performance with a 7% rise in operating results and a 1% increase in fully franked dividends, driven by a strategic portfolio rotation favoring resource stocks aligned with global growth themes.

Lumos Diagnostics reported a strong surge in FebriDx® sales alongside positive FDA feedback, securing full Medicare reimbursement and advancing key clinical studies.

Wrkr Ltd has transitioned from development to deployment, launching key products and acquiring PaidRight to expand its payroll compliance offerings ahead of new legislation.

Triangle Energy has secured new offshore and onshore permits in the Philippines while initiating legal action against JV partners in Western Australia, signaling a strategic pivot and operational challenges ahead.

InhaleRx Limited has progressed its clinical trials for three drug candidates targeting cancer pain, panic disorder, and treatment-resistant depression, while securing additional funding and preparing for a company rebrand.

Inhalerx Limited reported a $628,000 cash burn in the December quarter while securing substantial funding facilities to advance its clinical trials. The company’s cash position and financing arrangements suggest a runway extending over 80 quarters at current spending levels.